{"id":"https://openalex.org/W7203909378","doi":"https://doi.org/10.6084/m9.figshare.33295425","title":"Supplemental Material for: Severe idiosyncratic drug-induced liver injury to Rivaroxaban and positive rechallenge with apixaban","display_name":"Supplemental Material for: Severe idiosyncratic drug-induced liver injury to Rivaroxaban and positive rechallenge with apixaban","alternate_titles":[],"publication_year":2026,"publication_date":"2026-08-20","ids":{"openalex":"https://openalex.org/W7203909378","doi":"https://doi.org/10.6084/m9.figshare.33295425"},"language":"en","primary_location":{"id":"doi:10.6084/m9.figshare.33295425","doi":"https://doi.org/10.6084/m9.figshare.33295425","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.33295425","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"parent_works":[],"lineage":["https://openalex.org/W7203909378"],"child_works_count":0,"type":"supplementary-materials","is_traditional":false,"indexed_in":["datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://doi.org/10.6084/m9.figshare.33295425","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5146365916","display_name":"figshare admin karger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162602","display_name":"Karger Publishers (Switzerland)","ror":"https://ror.org/0572q5a45","country_code":"CH","type":"company","lineage":["https://openalex.org/I2802626578","https://openalex.org/I40120149","https://openalex.org/I4210162602"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"figshare admin karger","raw_affiliation_strings":["Karger Publishers (Switzerland)"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Karger Publishers (Switzerland)","institution_ids":["https://openalex.org/I4210162602"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102262538","display_name":"Soumaya Mrabet","orcid":"https://orcid.org/0000-0002-1321-6674","observed_orcids":["https://orcid.org/0000-0002-1321-6674"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Soumaya Mrabet","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042364005","display_name":"Neila Fathallah","orcid":"https://orcid.org/0000-0001-9075-396X","observed_orcids":["https://orcid.org/0000-0001-9075-396X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Neila Fathallah","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013481962","display_name":"\u0623\u0633\u0645\u0627\u0621 \u0646\u0627\u0635\u0631","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Asma Nasr","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109541665","display_name":"Raida Harbi","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Raida Harbi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5147799786","display_name":"Sana Ben Amor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sana Ben Amor","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068951440","display_name":"Chaker Ben Salem","orcid":"https://orcid.org/0000-0001-5187-5809","observed_orcids":["https://orcid.org/0000-0001-5187-5809"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chaker Ben Salem","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089069300","display_name":"Bouraoui Ouni","orcid":"https://orcid.org/0009-0001-6380-8723","observed_orcids":["https://orcid.org/0009-0001-6380-8723"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bouraoui Ouni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041197830","display_name":"I. Akkari","orcid":"https://orcid.org/0000-0002-7953-6873","observed_orcids":["https://orcid.org/0000-0002-7953-6873"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Imen Akkari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5112586648","display_name":"Elhem Ben Jazia","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Elhem Ben Jazia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"reviewed_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11465","display_name":"Drug-Induced Hepatotoxicity and Protection","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0007999999797903001,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10285","display_name":"Venous Thromboembolism Diagnosis and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2724","display_name":"Internal Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":0.9459999799728394},{"id":"https://openalex.org/keywords/drug-induced-liver-injury","display_name":"drug-induced liver injury","score":0.8619999885559082},{"id":"https://openalex.org/keywords/apixaban","display_name":"apixaban","score":0.8619999885559082},{"id":"https://openalex.org/keywords/direct-oral-anticoagulants","display_name":"direct oral anticoagulants","score":0.8809999823570251},{"id":"https://openalex.org/keywords/factor-xa-inhibitors","display_name":"factor Xa inhibitors","score":0.8920000195503235},{"id":"https://openalex.org/keywords/cross-reactivity","display_name":"cross-reactivity","score":0.8230000138282776},{"id":"https://openalex.org/keywords/idiosyncratic-hepatotoxicity","display_name":"idiosyncratic hepatotoxicity","score":0.7940000295639038},{"id":"https://openalex.org/keywords/acenocoumarol","display_name":"acenocoumarol","score":0.9520000219345093},{"id":"https://openalex.org/keywords/naranjo-scale","display_name":"Naranjo scale","score":0.7689999938011169},{"id":"https://openalex.org/keywords/rucam-score","display_name":"RUCAM score","score":0.9509999752044678},{"id":"https://openalex.org/keywords/jaundice","display_name":"jaundice","score":0.597000002861023},{"id":"https://openalex.org/keywords/hyperbilirubinemia","display_name":"hyperbilirubinemia","score":0.7900000214576721},{"id":"https://openalex.org/keywords/prothrombin-time","display_name":"prothrombin time","score":0.7850000262260437}],"concepts":[{"id":"https://openalex.org/C2780638905","wikidata":"https://www.wikidata.org/wiki/Q414462","display_name":"Apixaban","level":5,"score":0.9672999978065491},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.949999988079071},{"id":"https://openalex.org/C2778661090","wikidata":"https://www.wikidata.org/wiki/Q420262","display_name":"Rivaroxaban","level":4,"score":0.8707000017166138},{"id":"https://openalex.org/C2776637226","wikidata":"https://www.wikidata.org/wiki/Q6658207","display_name":"Liver injury","level":2,"score":0.6133999824523926},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.476500004529953},{"id":"https://openalex.org/C2779161974","wikidata":"https://www.wikidata.org/wiki/Q815819","display_name":"Atrial fibrillation","level":2,"score":0.4381999969482422},{"id":"https://openalex.org/C3020359197","wikidata":"https://www.wikidata.org/wiki/Q1359801","display_name":"Liver enzyme","level":2,"score":0.4277999997138977},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.426800012588501},{"id":"https://openalex.org/C2778722691","wikidata":"https://www.wikidata.org/wiki/Q57055","display_name":"Acetaminophen","level":2,"score":0.4065000116825104},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.39629998803138733},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3921999931335449},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.37049999833106995},{"id":"https://openalex.org/C2778810321","wikidata":"https://www.wikidata.org/wiki/Q419345","display_name":"Dabigatran","level":4,"score":0.33570000529289246},{"id":"https://openalex.org/C3018561737","wikidata":"https://www.wikidata.org/wiki/Q929737","display_name":"Liver damage","level":2,"score":0.32100000977516174},{"id":"https://openalex.org/C2780434524","wikidata":"https://www.wikidata.org/wiki/Q1144385","display_name":"Prothrombin time","level":2,"score":0.3116999864578247},{"id":"https://openalex.org/C41260117","wikidata":"https://www.wikidata.org/wiki/Q668064","display_name":"Hepatology","level":2,"score":0.304500013589859},{"id":"https://openalex.org/C2778382381","wikidata":"https://www.wikidata.org/wiki/Q179217","display_name":"Coagulation","level":2,"score":0.2980000078678131},{"id":"https://openalex.org/C512861765","wikidata":"https://www.wikidata.org/wiki/Q1359801","display_name":"Liver function tests","level":2,"score":0.2962999939918518},{"id":"https://openalex.org/C50440223","wikidata":"https://www.wikidata.org/wiki/Q1475848","display_name":"Risk factor","level":2,"score":0.29589998722076416},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.2883000075817108},{"id":"https://openalex.org/C2908529173","wikidata":"https://www.wikidata.org/wiki/Q890200","display_name":"Coagulation Disorder","level":3,"score":0.28679999709129333},{"id":"https://openalex.org/C2992872382","wikidata":"https://www.wikidata.org/wiki/Q305481","display_name":"Alanine aminotransferase","level":2,"score":0.2809999883174896},{"id":"https://openalex.org/C2778456037","wikidata":"https://www.wikidata.org/wiki/Q133244","display_name":"Jaundice","level":2,"score":0.2709999978542328}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.6084/m9.figshare.33295425","doi":"https://doi.org/10.6084/m9.figshare.33295425","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.33295425","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},{"id":"doi:10.6084/m9.figshare.33295425.v1","doi":"https://doi.org/10.6084/m9.figshare.33295425.v1","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.33295425.v1","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"}],"best_oa_location":{"id":"doi:10.6084/m9.figshare.33295425","doi":"https://doi.org/10.6084/m9.figshare.33295425","is_oa":true,"landing_page_url":"https://doi.org/10.6084/m9.figshare.33295425","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Dataset"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2325558389","https://openalex.org/W3158278497","https://openalex.org/W2783135992","https://openalex.org/W4403720916","https://openalex.org/W2922271347","https://openalex.org/W4387009446","https://openalex.org/W2580614884","https://openalex.org/W2176031852","https://openalex.org/W2921767782","https://openalex.org/W7208764714"],"abstract_inverted_index":{"Introduction:":[0],"Rivaroxaban,":[1],"a":[2,53,142,149,189,224],"direct":[3,39],"oral":[4,40],"factor":[5,200],"Xa":[6,201],"inhibitor,":[7],"is":[8],"widely":[9],"used":[10],"for":[11,35],"the":[12,50,118,135],"prevention":[13],"and":[14,58,77,93,107,117,126,138,161,173,214],"treatment":[15],"of":[16,25,52,70,80,207,226],"thromboembolic":[17],"disorders.":[18],"Although":[19],"generally":[20],"well":[21],"tolerated,":[22],"rare":[23,209],"cases":[24],"drug-induced":[26],"liver":[27,81,159,228],"injury":[28],"(DILI)":[29],"have":[30],"been":[31],"reported.":[32],"The":[33],"potential":[34,196],"cross-reactivity":[36],"with":[37,56,75,100,175,188,223],"other":[38],"anticoagulants":[41],"(DOACs)":[42],"remains":[43],"poorly":[44],"documented.":[45],"Case":[46],"Presentation:":[47],"We":[48],"report":[49],"case":[51,183],"76-year-old":[54],"woman":[55],"hypertension":[57],"cardiac":[59],"arrhythmia":[60],"who":[61],"developed":[62],"severe":[63,113,185],"acute":[64],"DILI":[65,114],"six":[66],"months":[67,146],"after":[68],"initiation":[69],"rivaroxaban":[71],"therapy.":[72],"She":[73],"presented":[74],"jaundice":[76],"marked":[78],"elevation":[79],"enzymes":[82,160],"(AST":[83],"19\u00d7":[84],"upper":[85,90,96],"normal":[86,91,97],"limit,":[87],"ALT":[88],"9\u00d7":[89],"limit)":[92],"hyperbilirubinemia":[94],"(20\u00d7":[95],"limit),":[98],"associated":[99],"impaired":[101],"prothrombin":[102],"time":[103],"(<10%).":[104],"Viral,":[105],"autoimmune,":[106],"obstructive":[108],"causes":[109],"were":[110],"excluded.":[111],"Rivaroxaban-induced":[112],"was":[115,120,154,170],"suspected,":[116],"drug":[119],"discontinued,":[121],"resulting":[122],"in":[123,221],"progressive":[124],"clinical":[125],"biochemical":[127],"recovery":[128],"within":[129],"three":[130],"weeks.":[131],"Causality":[132],"assessment":[133],"using":[134],"Naranjo":[136],"scale":[137],"RUCAM":[139],"score":[140],"indicated":[141],"probable":[143],"relationship.":[144],"Six":[145],"later,":[147],"following":[148,192],"cerebrovascular":[150],"ischemic":[151],"event,":[152],"apixaban":[153,193],"introduced.":[155],"Within":[156],"four":[157],"days,":[158],"coagulation":[162],"parameters":[163],"worsened":[164],"again,":[165],"suggesting":[166,195],"possible":[167,190],"cross-reactivity.":[168],"Apixaban":[169],"immediately":[171],"discontinued":[172],"replaced":[174],"acenocoumarol,":[176],"leading":[177],"to":[178],"favorable":[179],"outcome.":[180],"Conclusion:":[181],"This":[182],"highlights":[184],"rivaroxaban-induced":[186],"hepatotoxicity":[187,198],"relapse":[191],"exposure,":[194],"class-related":[197],"among":[199],"inhibitors.":[202],"Clinicians":[203],"should":[204],"be":[205],"aware":[206],"this":[208],"but":[210],"serious":[211],"adverse":[212],"effect":[213],"exercise":[215],"caution":[216],"when":[217],"switching":[218],"between":[219],"DOACs":[220],"patients":[222],"history":[225],"anticoagulant-induced":[227],"injury.":[229]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W7203909378","counts_by_year":[],"updated_date":"2026-10-28T10:33:24.094632","created_date":"2026-08-22T00:00:00"}
